Issues pertaining to Pharmacy Benefit Managers Step therapy reform -the Safe Step Act Neuroscience Drug Program - FY 2026 AgFDA Approps BRAIN Initiative - FY 2026 Labor-HHS Appropriations Migraine care - FY 2026 MilCon Approps
Source-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- Not reported
- Expenses
- $140,000.00
- Registrant
- LUNDBECK LLC
- Client
- LUNDBECK LLC
- Filing UUID
- 3a714fd6-00ba-4a24-b4db-9f6e3ee15b20
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues pertaining to the 340B Drug Discount Program Issues pertaining to the implementation of the Inflation Reduction Act of 2022 Issues pertaining to Pharmacy Benefit Managers Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 - The ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832 - The EPIC Act
Literal federal measure citations: H.R. 946, H.R. 1492, S. 832
R&D Tax Credit
Tariffs on pharmaceutical products
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.